Characterization of carfilzomib-resistant non-small cell lung cancer cell lines

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Michael I. Love, Wolfgang Huber, Simon Anders · Genome biology · 2014 · 100.5K citations · Full text

Life Sciences, Bioinformatics, Biostatistics +15

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Teru Hideshima, Paul G. Richardson, D Chauhan et al. · PubMed · 2001 · 1.5K citations

Medicine, Oncology, Pharmacology +17

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

David S. Siegel, Thomas G. Martin, Michael Wang et al. · Blood · 2012 · 655 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Owen A. O’Connor, Craig H. Moskowitz, Jamie Muzzy et al. · Journal of Clinical Oncology · 2004 · 579 citations

Medicine, Hematology, Pharmacology +17

Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein

Ruud Oerlemans, N. Franke, Yehuda G. Assaraf et al. · Blood · 2008 · 449 citations

Life Sciences, Biochemistry, Molecular Biology +13